| abstract |
The invention relates to a method for predicting responsiveness of a cancer in a subject to treatment with an Mcl-1 inhibitor and optionally a Bcl-2 or Bcl-xL inhibitor, a method for identifying a subject with a cancer unsuitable for treatment with an Mcl-1 inhibitor and optionally a Bcl-2 or Bc1-xL inhibitor, and a method for treating a cancer in a subject, comprising administering to the subject an Mc1-l inhibitor and optionally a Bcl-2 or Bc1-xL inhibitor. Each method comprises detecting Bak expression in a sample of the cancer. The invention also relates to a method of identifying a compound which inhibits Mcl-1 and a kinase by determining the effect of the compound on either CDK7 or CDK9 and either PI3K or FLT3 kinase activity. |